Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in Elderly Men with mCRPC Post-Docetaxel
NCT01750866Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Feb 2013
- Primary completion
- Oct 2013
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Progression-Free Survival up to 30 weeks. Planned start Feb 2013; status: withdrawn.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01750866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01750866.